Cours suspendu

Communiqués Adaptimmune Therapeutics plc Börse Stuttgart

Actions

473A

US00653A1079

Produits pharmaceutiques

Marché Fermé - Börse Stuttgart Autres places de cotation 11:04:00 21/05/2026			Varia. 5j.	Varia. 1 janv.
0,0100 ^EUR	-.--%		-41,18%	-9,09%

19/05	Adaptimmune Therapeutics plc publie ses résultats pour l'exercice clos le 31 décembre 2025	CI
17/11	Adaptimmune Therapeutics plc annonce des changements à sa direction générale	CI

Communiqués

17/11	Adaptimmune Announces Changes to Board and Executive Leadership Team	NE
20/10/25	Adaptimmune Announces Delisting from Nasdaq	NE
13/08/25	Adaptimmune Reports Q2 Financial Results and Provides Business Update	NE
28/07/25	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds	NE
13/05/25	Adaptimmune Reports Q1 Financial Results and Provides Business Update	NE
07/05/25	Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025	NE
25/03/25	Adaptimmune Therapeutics : Transcript Q4 & FY 2024	PU
20/03/25	Adaptimmune Therapeutics : Earnings Release Q4 & FY 2024	PU
20/03/25	Adaptimmune Provides Q4 and Full Year 2024 Business Update	NE
12/03/25	Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025	NE
30/01/25	Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025	NE
13/01/25	Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)	NE
19/12/24	Adaptimmune Therapeutics : Announces Changes to its Executive Leadership Team Based in the UK Form 8 K	PU
19/12/24	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK	NE
02/12/24	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)	NE
13/11/24	Adaptimmune Therapeutics : Reports Q3 2024 Financial and Business Updates Form 8 K	PU
13/11/24	Adaptimmune Reports Q3 2024 Financial and Business Updates	NE
13/11/24	Adaptimmune Therapeutics : Lete cel Achieves Primary Endpoint in Pivotal Trial Form 8 K	PU
13/11/24	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial	NE
05/11/24	Adaptimmune to Participate in Scientific and Medical Conferences this November and December	NE
31/10/24	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024	NE
28/08/24	Adaptimmune to Participate in Two Bank Conferences this September	NE
14/08/24	Adaptimmune Therapeutics : Transcript Q2 2024	PU
12/08/24	Adaptimmune Therapeutics : Earnings Release Q2 2024	PU
12/08/24	Adaptimmune Reports Q2 2024 Financial and Business Updates	NE